BENOXAPROFEN


Synonyms	Benoxaprofen COMPD 90459 COMPOUND 90459 Coxigon NSC-299582 Opren Oraflex
Status
Molecule Category	UNKNOWN
ATC	M01AE06
UNII	17SZX404IM
EPA CompTox	DTXSID4022650


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	MITFXPHMIHQXPI-UHFFFAOYSA-N
Smiles	CC(C(=O)O)c1ccc2oc(-c3ccc(Cl)cc3)nc2c1
InChI	InChI=1S/C16H12ClNO3/c1-9(16(19)20)11-4-7-14-13(8-11)18-15(21-14)10-2-5-12(17)6-3-10/h2-9H,1H3,(H,19,20)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C16H12ClNO3
Molecular Weight	301.73
AlogP	4.34
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	3.0
Polar Surface Area	63.33
Molecular species	ACID
Aromatic Rings	3.0
Heavy Atoms	21.0

Bioactivity

Mechanism of Action	Action	Reference
Arachidonate 12-lipoxygenase inhibitor	INHIBITOR	PubMed PubMed PubMed PubMed PubMed PubMed PubMed


Protein: Arachidonate 12-lipoxygenase Description: Polyunsaturated fatty acid lipoxygenase ALOX12 Organism : Homo sapiens P18054 ENSG00000108839

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Transporter Primary active transporter ATP-binding cassette ABCB subfamily	-	99100	-	-	-

Assay Description	Organism	Bioactivity	Reference
Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered as two doses 3 and 0.5 hr prior to challenge measured 2.5 hrs post challenge	Rattus norvegicus	78.0 %

Cross References

Resources	Reference
ChEBI	76114
ChEMBL	CHEMBL340978
DrugBank	DB04812
DrugCentral	311
FDA SRS	17SZX404IM
PubChem	39941
SureChEMBL	SCHEMBL24413

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).